

# GÃœevenÃ KoÃkaya

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8467552/publications.pdf>

Version: 2024-02-01

25  
papers

75  
citations

1684188

5  
h-index

1588992

8  
g-index

27  
all docs

27  
docs citations

27  
times ranked

74  
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of patient access to orphan drugs in Turkey. Orphanet Journal of Rare Diseases, 2021, 16, 68.	2.7	11
2	Changes in Catastrophic Health Expenditures Depending on Health Policies in Turkey. Frontiers in Public Health, 2020, 8, 614449.	2.7	4
3	Analysis of Market Access Agreements in Turkey. Farmeconomia E Percorsi Terapeutici, 2020, 21, .	0.1	0
4	Cost analysis of management of cardiovascular disease comorbidities in Turkey. Journal of Pharmaceutical Health Services Research, 2019, 10, 197-202.	0.6	3
5	Increasing Trend On Turkish Un-Licensed Medicine Market: A General Overview Analysis. Value in Health, 2017, 20, A668-A669.	0.3	0
6	Direct Cost Of Hiv/Aids In Turkey. Value in Health, 2016, 19, A411-A412.	0.3	1
7	Impact of Health Policy Changes on Trends in the Pharmaceutical Market in Turkey. Value in Health Regional Issues, 2016, 10, 48-52.	1.2	6
8	Analysis of the treatment cost of HIV/AIDS in Turkey. Farmeconomia E Percorsi Terapeutici, 2016, 17, 13-17.	0.1	6
9	Cost-effectiveness analysis of oral anti-viral drugs used for treatment of chronic hepatitis B in Turkey. Cost Effectiveness and Resource Allocation, 2015, 13, 21.	1.5	4
10	The Most Profitable Health Insurance "Company" In Turkey. Value in Health, 2015, 18, A538.	0.3	0
11	Improving cost-efficiency at a hospital by showing the time-saving effect of using different neuromuscular blockers for short operations. Journal of Pharmaceutical Health Services Research, 2014, 5, 61-66.	0.6	1
12	Value of Life And Cost of Pre-Mature Deaths With The Perspective Of Productivity As Net Tax Revenue: A Comparison In Argentina, Brazil And Mexico. Value in Health, 2014, 17, A425.	0.3	0
13	Value of Life And Cost of Pre-Mature Deaths With The Perspective Of Productivity As Net Tax Revenue: A Comparison In Usa, Canada, Japan and Australia. Value in Health, 2014, 17, A423.	0.3	0
14	Value of Life and Cost of Pre-Mature Deaths With The Perspective of Productivity As Net Tax Revenue: A Comparison in France, Germany, Italy, Spain, United Kingdom. Value in Health, 2014, 17, A424.	0.3	0
15	An Overview of the Orphan Medicines Market in Turkey. Value in Health Regional Issues, 2014, 4, 47-52.	1.2	10
16	Orphan drug regulations in Turkey. Journal of Pharmaceutical Health Services Research, 2013, 4, 151-153.	0.6	7
17	Treatment cost of metastatic colon cancer in Turkey. Farmeconomia E Percorsi Terapeutici, 2013, 14, 19-25.	0.1	2
18	Results of reference pricing and reimbursement discount rate schemes of Turkey. Farmeconomia E Percorsi Terapeutici, 2013, 14, 99-103.	0.1	0

#	ARTICLE	IF	CITATIONS
19	Compassionate medicine-use programmes in Turkey: a report on current status. Journal of Pharmaceutical Health Services Research, 2012, 3, 129-134.	0.6	2
20	PHP141 Effects of Changing Health Policy on Pharmacoeconomics and Health Outcome Studies in Turkey. Value in Health, 2012, 15, A313-A314.	0.3	0
21	Off-label and unlicensed oncology medicine use in Turkey: a retrospective analysis of computer records of the Turkish Ministry of Health. Journal of Pharmaceutical Health Services Research, 2011, 2, 53-57.	0.6	3
22	Can We Reduce the Cost of Illness With More Compliant Patients? An Estimation of the Effect of 100% Compliance With Hypertension Treatment. Journal of Pharmacy Practice, 2011, 24, 345-350.	1.0	13
23	Considering the cost-effectiveness of statins in family practice in Turkey from a payer perspective. Health, 2009, 01, 274-280.	0.3	2
24	Determining the impact of vitamin C use with the common cold on loss of labour and medical treatment costs for Turkey. Journal of Pharmaceutical Health Services Research, 0, , .	0.6	0
25	Corrigendum to: Determining the impact of vitamin C use with the common cold on loss of labour and medical treatment costs for Turkey. Journal of Pharmaceutical Health Services Research, 0, , .	0.6	0